RxDoctor Payments Data

Charles Fuenning, MD

Pulmonary Disease · Cuyahoga Falls, OHNPI 1972513406

Payments from drug & device makers

$16,941in general payments, 2019–2025

Across 492 payments — averaging $34.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • Regeneron Healthcare Solutions, Inc.$2K
  • GSK$2K
  • Boehringer Ingelheim$862
  • United Therapeutics Corporation$636
  • Sanofi$619
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$1,86911%
  • Speaking & faculty fees$5,90035%
  • Food & beverage$9,01953%
  • Education$1531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,941 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$88,553
Medicare patients
618
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate34$420,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter426$381,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol379$334,185
GlassiaAlpha-1-Proteinase Inhibitor13$182,026
Spiriva RespimatTiotropium Bromide153$124,664
Stiolto RespimatTiotropium Br/Olodaterol Hcl174$103,910
Fasenra PenBenralizumab11$67,037
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr107$62,558
Breo ElliptaFluticasone/Vilanterol101$57,682
NucalaMepolizumab15$55,313
Advair HfaFluticasone Propion/Salmeterol105$47,257
SymbicortBudesonide/Formoterol Fumarate119$43,144
Fluticasone-SalmeterolFluticasone Propion/Salmeterol237$39,089
Arnuity ElliptaFluticasone Furoate107$37,698
DuleraMometasone/Formoterol46$28,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$862$658,502373 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta$1,627$613,130793 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler$7,655$388,755523 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$231$182,02613 claims
MerckDulera$146$28,03146 claims
PfizerEliquis$67$17,31729 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$160$8,56822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cuyahoga Falls

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →